|
시장보고서
상품코드
2018373
아미트리프틸린 염산염 시장 규모, 점유율, 동향 분석 보고서 : 제형별, 적응증별, 유통 채널별, 지역별, 부문별 예측(2026-2033년)Amitriptyline Hydrochloride Market Size, Share & Trends Analysis Report By Dosage Form, (Oral Solid Dosage Forms, Oral Liquid Formulations), By Indication, By Distribution Channel, By Region, And Segment Forecasts, 2026 - 2033 |
||||||
아미트리프틸린 염산염 시장 요약
세계의 아미트리프틸린 염산염 시장 규모는 2025년에 3억 8,117만 달러로 추정되며, 2033년까지 5억 1,020만 달러에 달할 것으로 예측되며, 2026년부터 2033년까지 CAGR 3.78%로 성장할 것으로 전망됩니다.
전 세계 아미트리프틸린 염산염 시장은 전 세계 다양한 연령층에서 우울증, 불안장애, 만성 통증의 유병률이 증가함에 따라 성장하고 있습니다.
정신건강에 대한 인식이 높아짐에 따라 진단율이 향상되고, 임상 현장 전반에서 치료 채택이 증가하고 있습니다. 아미트리프틸린은 신경인성 통증, 편두통 예방 및 특정 수면 장애에 대한 처방이 계속되고 있어 그 치료적 중요성이 높아지고 있습니다. 다년간의 임상적 성과와 의사들의 친숙함은 일차의료 및 전문 의료 현장에서의 일관된 처방행위를 뒷받침하고 있습니다. 외래진료소 및 정신보건시설에 대한 환자 방문 증가가 수요 유지에 기여하고 있습니다. 예를 들어, 2025년 8월 세계보건기구(WHO)는 전 세계적으로 약 3억 3,200만 명이 우울증을 앓고 있으며, 이는 전 세계 인구의 약 4%에 해당한다고 보고했습니다. 이는 항우울제 치료를 필요로 하는 환자층이 매우 크다는 것을 보여줍니다. 도시화, 생활습관에 따른 스트레스, 만성질환의 부담 증가도 처방량에 영향을 미쳐 장기적으로 세계 시장 확대에 영향을 미치고 있습니다.
제네릭 의약품의 풍부한 공급은 여러 지역에서 시장 성장을 뒷받침하는 중요한 요인으로 작용하고 있습니다. 비용 효율적인 제조를 통해 제약회사는 경쟁력 있는 가격으로 대량 공급이 가능해져 환자의 접근성을 향상시킬 수 있습니다. 제네릭 의약품과의 경쟁은 의료 서비스 제공자 간의 수요를 일정하게 유지하면서 가격 안정화를 촉진해 왔습니다. 제약사들은 시장에서의 입지를 강화하기 위해 생산 효율성, 품질 기준, 유통 네트워크의 최적화를 지속적으로 추진하고 있습니다. 소매 약국 체인 및 의약품 EC 플랫폼의 확장은 도시 및 교외 지역 주민들의 의약품 접근성을 개선하고 있습니다. 병원에서는 만성 신경질환 및 정신질환에 대한 지속적인 치료 수요가 있기 때문에 안정적인 조달 수준을 유지하고 있습니다.
예를 들어, 2025년 최신 통계에 따르면, 전미정신질환연맹(NAMI)은 2024년 약 6,150만 명의 미국 성인이 정신질환을 경험하게 될 것이며, 이는 성인 인구의 23.4%에 해당한다고 보고했습니다. 한편, 정신질환을 앓고 있는 성인의 52.1%가 치료를 받고 있는 것으로 나타나, 의료 시스템 전반에 걸쳐 치료의 보급이 진행되고 있음을 알 수 있습니다. 신뢰할 수 있는 공급망과 기존 공급업체와의 관계는 예측 가능한 구매 행동에 기여하고, 시장 진입 기업의 지속적인 수익 창출을 지원합니다.
전 세계 고령화의 진전은 아미트리프틸린 염산염의 수요에 크게 기여하고 있습니다. 노인들은 신경인성 통증과 우울증의 발병률이 높기 때문입니다. 섬유근육통, 만성두통 등 적응증 외 사용의 임상적 활용이 증가하면서 치료 용도가 확대되고 있습니다. 제약 제조 기술의 발전으로 각 생산 시설의 제품 균일성, 확장성 및 규제 준수율이 향상되고 있습니다. 개발도상국의 의료 인프라 확충은 만성질환의 진단율과 치료 접근성을 향상시키고 있습니다.
예를 들어, 2025년 세계보건기구(WHO)는 정신질환이 여전히 세계 10대 건강 손실의 주요 원인 중 하나이며, 우울증과 불안장애가 모든 연령층에서 가장 흔한 질병이라고 보고했습니다. 이는 치료적 개입에 대한 수요를 뒷받침합니다. 의사들 사이에서 효능이 입증된 알려진 약물에 대한 선호도가 높아지면서 처방량이 지속적으로 유지되고 있습니다. 평균 수명의 연장과 만성질환의 유병률 증가는 지속적인 치료 수요를 창출하여 세계 아미트리프틸린 염산염 산업의 안정적이고 장기적인 성장 전망에 기여하고 있습니다.
자주 묻는 질문
목차
제1장 조사 방법과 범위
제2장 주요 요약
제3장 아미트리프틸린 염산염 시장 : 변수, 동향, 범위
제4장 아미트리프틸린 염산염 시장 : 제형별 비즈니스 분석
제5장 아미트리프틸린 염산염 시장 : 적응증별 비즈니스 분석
제6장 아미트리프틸린 염산염 시장 : 유통 채널별 비즈니스 분석
제7장 아미트리프틸린 염산염 시장 : 지역별 추정·동향 분석
제8장 경쟁 구도
KSM 26.05.13Amitriptyline Hydrochloride Market Summary
The global amitriptyline hydrochloride market size was estimated at USD 381.17 million in 2025 and is projected to reach USD 510.20 million by 2033, growing at a CAGR of 3.78% from 2026 to 2033. The global amitriptyline hydrochloride industry is expanding due to the rising prevalence of depression, anxiety disorders, and chronic pain conditions across diverse age groups worldwide.
Growing awareness surrounding mental health has improved diagnosis rates and increased treatment adoption across clinical settings. Amitriptyline continues to be prescribed for neuropathic pain, migraine prevention, and certain sleep disorders, which strengthens its therapeutic relevance. Its long-established clinical history and physician familiarity support consistent prescribing behavior across primary and specialty care. Increasing patient visits to outpatient clinics and mental health facilities helps sustain demand. For instance, in August 2025, the World Health Organization reported that approximately 332 million people worldwide were living with depression, representing about 4% of the global population, highlighting the large patient pool requiring antidepressant treatment. Urbanization, lifestyle stress, and the rising chronic disease burden further influence prescription volumes, supporting long-term global market expansion.
The strong availability of generic formulations represents a key factor supporting market growth across multiple regions. Cost-efficient manufacturing enables pharmaceutical companies to supply large volumes at competitive prices, thereby improving patient access. Generic competition has encouraged pricing stability while maintaining consistent demand among healthcare providers. Pharmaceutical manufacturers continue to optimize production efficiency, quality standards, and distribution networks to strengthen market presence. The expansion of retail pharmacy chains and e-commerce pharmaceutical platforms improves access to medicine across urban and semi-urban populations. Hospitals maintain steady procurement levels due to ongoing treatment needs for chronic neurological and psychiatric conditions.
For instance, in 2025 updated statistics, the National Alliance on Mental Illness reported that about 61.5 million U.S. adults experienced mental illness in 2024, representing 23.4% of the adult population, while 52.1% of adults with mental illness received treatment, indicating growing treatment adoption across healthcare systems. Reliable supply chains and established supplier relationships contribute to predictable purchasing behavior, supporting sustained revenue generation for market participants.
The growing global aging population contributes significantly to demand for amitriptyline hydrochloride, as older individuals experience higher rates of neuropathic pain and depressive symptoms. Increasing clinical use in off-label indications, including fibromyalgia and chronic headache disorders, expands therapeutic utilization. Improvements in pharmaceutical manufacturing technologies enhance product consistency, scalability, and regulatory compliance across production facilities. Expanding healthcare infrastructure in developing economies improves diagnosis rates and access to treatment for chronic conditions.
For instance , in 2025, the World Health Organization reported that mental health conditions remained among the top 10 leading causes of health loss worldwide, with depression and anxiety identified as the most common disorders across age groups, reinforcing the demand for therapeutic interventions. Rising physician preference for established medications with known efficacy profiles supports continued prescription levels. Longer life expectancy and increased chronic disease prevalence create recurring treatment requirements, contributing to stable long-term growth prospects for the amitriptyline hydrochloride industry globally.
Global Amitriptyline Hydrochloride Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global amitriptyline hydrochloride market report based on dosage form, indication, distribution channel, and region:
- Dosage Form Outlook (Revenue, USD Million, 2021 - 2033)
- Oral Solid Dosage Forms
- Oral Liquid Formulations
- Indication Outlook (Revenue, USD Million, 2021 - 2033)
- Major Depressive Disorder
- Neuropathic Pain
- Migraine Prophylaxis
- Other Indications
- Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Others
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Dosage Form
- 1.2.2. Indication
- 1.2.3. Distribution Channel
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
- 1.6. Information Analysis
- 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Data Visualization
- 1.8. Model Details
- 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Amitriptyline Hydrochloride Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
- 3.3.1.1. Supplier Power
- 3.3.1.2. Buyer Power
- 3.3.1.3. Substitution Threat
- 3.3.1.4. Threat of New Entrants
- 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
- 3.3.3. Pipeline Analysis
- 3.3.4. Patent Expiry Analysis
- 3.3.5. Pricing Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
Chapter 4. Amitriptyline Hydrochloride Market: Dosage Form Business Analysis
- 4.1. Dosage Form Market Share, 2025 & 2033
- 4.2. Dosage Form Segment Dashboard
- 4.3. Market Size & Forecasts and Trend Analysis, by Dosage Form, 2021 to 2033 (USD Million)
- 4.4. Oral Solid Dosage Forms
- 4.4.1. Oral Solid Dosage Forms Market, 2021 - 2033 (USD Million)
- 4.5. Oral Liquid Formulations
- 4.5.1. Oral Liquid Formulations Market, 2021 - 2033 (USD Million)
Chapter 5. Amitriptyline Hydrochloride Market: Indication Business Analysis
- 5.1. Indication Market Share, 2025 & 2033
- 5.2. Indication Segment Dashboard
- 5.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Million)
- 5.4. Major Depressive Disorder
- 5.4.1. Major Depressive Disorder Market, 2021 - 2033 (USD Million)
- 5.5. Neuropathic Pain
- 5.5.1. Neuropathic Pain Market, 2021 - 2033 (USD Million)
- 5.6. Migraine Prophylaxis
- 5.6.1. Migraine Prophylaxis Market, 2021 - 2033 (USD Million)
- 5.7. Other Indications
- 5.7.1. Other Indications Market, 2021 - 2033 (USD Million)
Chapter 6. Amitriptyline Hydrochloride Market: Distribution Channel Business Analysis
- 6.1. Distribution Channel Market Share, 2025 & 2033
- 6.2. Distribution Channel Segment Dashboard
- 6.3. Market Size & Forecasts and Trend Analysis, by Distribution channel, 2021 to 2033 (USD Million)
- 6.4. Hospital Pharmacies
- 6.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
- 6.5. Retail Pharmacies
- 6.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
- 6.6. Others
- 6.6.1. Others Market, 2021 - 2033 (USD Million)
Chapter 7. Amitriptyline Hydrochloride Market: Regional Estimates & Trend Analysis
- 7.1. Regional Market Share Analysis, 2025 & 2033
- 7.2. Regional Market Dashboard
- 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
- 7.4. North America
- 7.4.1. North America Amitriptyline Hydrochloride Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
- 7.4.2. U.S.
- 7.4.2.1. Key Country Dynamics
- 7.4.2.2. Target Disease Prevalence
- 7.4.2.3. Regulatory Framework
- 7.4.2.4. Reimbursement Framework
- 7.4.2.5. U.S. Amitriptyline Hydrochloride Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.3. Canada
- 7.4.3.1. Key Country Dynamics
- 7.4.3.2. Target Disease Prevalence
- 7.4.3.3. Regulatory Framework
- 7.4.3.4. Reimbursement Framework
- 7.4.3.5. Canada Amitriptyline Hydrochloride Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.4. Mexico
- 7.4.4.1. Key Country Dynamics
- 7.4.4.2. Target Disease Prevalence
- 7.4.4.3. Regulatory Framework
- 7.4.4.4. Reimbursement Framework
- 7.4.4.5. Mexico Amitriptyline Hydrochloride Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5. Europe
- 7.5.1. Europe Amitriptyline Hydrochloride Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.2. UK
- 7.5.2.1. Key Country Dynamics
- 7.5.2.2. Target Disease Prevalence
- 7.5.2.3. Regulatory Framework
- 7.5.2.4. Reimbursement Framework
- 7.5.2.5. UK Amitriptyline Hydrochloride Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.3. Germany
- 7.5.3.1. Key Country Dynamics
- 7.5.3.2. Target Disease Prevalence
- 7.5.3.3. Regulatory Framework
- 7.5.3.4. Reimbursement Framework
- 7.5.3.5. Germany Amitriptyline Hydrochloride Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.4. France
- 7.5.4.1. Key Country Dynamics
- 7.5.4.2. Target Disease Prevalence
- 7.5.4.3. Regulatory Framework
- 7.5.4.4. Reimbursement Framework
- 7.5.4.5. France Amitriptyline Hydrochloride Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.5. Italy
- 7.5.5.1. Key Country Dynamics
- 7.5.5.2. Target Disease Prevalence
- 7.5.5.3. Regulatory Framework
- 7.5.5.4. Reimbursement Framework
- 7.5.5.5. Italy Amitriptyline Hydrochloride Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.6. Spain
- 7.5.6.1. Key Country Dynamics
- 7.5.6.2. Target Disease Prevalence
- 7.5.6.3. Regulatory Framework
- 7.5.6.4. Reimbursement Framework
- 7.5.6.5. Spain Amitriptyline Hydrochloride Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.7. Denmark
- 7.5.7.1. Key Country Dynamics
- 7.5.7.2. Target Disease Prevalence
- 7.5.7.3. Regulatory Framework
- 7.5.7.4. Reimbursement Framework
- 7.5.7.5. Denmark Amitriptyline Hydrochloride Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.8. Sweden
- 7.5.8.1. Key Country Dynamics
- 7.5.8.2. Target Disease Prevalence
- 7.5.8.3. Regulatory Framework
- 7.5.8.4. Reimbursement Framework
- 7.5.8.5. Sweden Amitriptyline Hydrochloride Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.9. Norway
- 7.5.9.1. Key Country Dynamics
- 7.5.9.2. Target Disease Prevalence
- 7.5.9.3. Regulatory Framework
- 7.5.9.4. Reimbursement Framework
- 7.5.9.5. Norway Amitriptyline Hydrochloride Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6. Asia Pacific
- 7.6.1. Asia Pacific Amitriptyline Hydrochloride Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.2. Japan
- 7.6.2.1. Key Country Dynamics
- 7.6.2.2. Target Disease Prevalence
- 7.6.2.3. Regulatory Framework
- 7.6.2.4. Reimbursement Framework
- 7.6.2.5. Japan Amitriptyline Hydrochloride Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.3. China
- 7.6.3.1. Key Country Dynamics
- 7.6.3.2. Target Disease Prevalence
- 7.6.3.3. Regulatory Framework
- 7.6.3.4. Reimbursement Framework
- 7.6.3.5. China Amitriptyline Hydrochloride Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.4. India
- 7.6.4.1. Key Country Dynamics
- 7.6.4.2. Target Disease Prevalence
- 7.6.4.3. Regulatory Framework
- 7.6.4.4. Reimbursement Framework
- 7.6.4.5. India Amitriptyline Hydrochloride Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.5. Australia
- 7.6.5.1. Key Country Dynamics
- 7.6.5.2. Target Disease Prevalence
- 7.6.5.3. Regulatory Framework
- 7.6.5.4. Reimbursement Framework
- 7.6.5.5. Australia Amitriptyline Hydrochloride Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.6. South Korea
- 7.6.6.1. Key Country Dynamics
- 7.6.6.2. Target Disease Prevalence
- 7.6.6.3. Regulatory Framework
- 7.6.6.4. Reimbursement Framework
- 7.6.6.5. South Korea Amitriptyline Hydrochloride Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.7. Thailand
- 7.6.7.1. Key Country Dynamics
- 7.6.7.2. Target Disease Prevalence
- 7.6.7.3. Regulatory Framework
- 7.6.7.4. Reimbursement Framework
- 7.6.7.5. Thailand Amitriptyline Hydrochloride Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7. Latin America
- 7.7.1. Latin America Amitriptyline Hydrochloride Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.2. Brazil
- 7.7.2.1. Key Country Dynamics
- 7.7.2.2. Target Disease Prevalence
- 7.7.2.3. Regulatory Framework
- 7.7.2.4. Reimbursement Framework
- 7.7.2.5. Brazil Amitriptyline Hydrochloride Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.3. Argentina
- 7.7.3.1. Key Country Dynamics
- 7.7.3.2. Target Disease Prevalence
- 7.7.3.3. Regulatory Framework
- 7.7.3.4. Reimbursement Framework
- 7.7.3.5. Argentina Amitriptyline Hydrochloride Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8. Middle East and Africa
- 7.8.1. Middle East and Africa Amitriptyline Hydrochloride Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.2. South Africa
- 7.8.2.1. Key Country Dynamics
- 7.8.2.2. Target Disease Prevalence
- 7.8.2.3. Regulatory Framework
- 7.8.2.4. Reimbursement Framework
- 7.8.2.5. South Africa Amitriptyline Hydrochloride Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.3. Saudi Arabia
- 7.8.3.1. Key Country Dynamics
- 7.8.3.2. Target Disease Prevalence
- 7.8.3.3. Regulatory Framework
- 7.8.3.4. Reimbursement Framework
- 7.8.3.5. Saudi Arabia Amitriptyline Hydrochloride Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.4. UAE
- 7.8.4.1. Key Country Dynamics
- 7.8.4.2. Target Disease Prevalence
- 7.8.4.3. Regulatory Framework
- 7.8.4.4. Reimbursement Framework
- 7.8.4.5. UAE Amitriptyline Hydrochloride Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.5. Kuwait
- 7.8.5.1. Key Country Dynamics
- 7.8.5.2. Target Disease Prevalence
- 7.8.5.3. Regulatory Framework
- 7.8.5.4. Reimbursement Framework
- 7.8.5.5. Kuwait Amitriptyline Hydrochloride Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. Competitive Landscape
- 8.1. Participant Overview
- 8.2. Company Market Position Analysis
- 8.3. Company Categorization
- 8.4. Strategy Mapping
- 8.5. Company Profiles/Listing
- 8.5.1. Accord Healthcare Inc.
- 8.5.1.1. Overview
- 8.5.1.2. Financial Performance
- 8.5.1.3. Product Benchmarking
- 8.5.1.4. Strategic Initiatives
- 8.5.2. Viatris Inc.
- 8.5.2.1. Overview
- 8.5.2.2. Financial Performance
- 8.5.2.3. Product Benchmarking
- 8.5.2.4. Strategic Initiatives
- 8.5.3. Sandoz Inc.
- 8.5.3.1. Overview
- 8.5.3.2. Financial Performance
- 8.5.3.3. Product Benchmarking
- 8.5.3.4. Strategic Initiatives
- 8.5.4. Sun Pharmaceutical Industries Ltd.
- 8.5.4.1. Overview
- 8.5.4.2. Financial Performance
- 8.5.4.3. Product Benchmarking
- 8.5.4.4. Strategic Initiatives
- 8.5.5. Torrent Pharmaceuticals Ltd.
- 8.5.5.1. Overview
- 8.5.5.2. Financial Performance
- 8.5.5.3. Product Benchmarking
- 8.5.5.4. Strategic Initiatives
- 8.5.6. Dr. Reddy's Laboratories
- 8.5.6.1. Overview
- 8.5.6.2. Financial Performance
- 8.5.6.3. Product Benchmarking
- 8.5.6.4. Strategic Initiatives
- 8.5.7. Unichem Laboratories Ltd.
- 8.5.7.1. Overview
- 8.5.7.2. Financial Performance
- 8.5.7.3. Product Benchmarking
- 8.5.7.4. Strategic Initiatives
- 8.5.8. Zydus Pharmaceuticals (Zydus Lifesciences)
- 8.5.8.1. Overview
- 8.5.8.2. Financial Performance
- 8.5.8.3. Product Benchmarking
- 8.5.8.4. Strategic Initiatives
- 8.5.9. Watson Laboratories Inc. (part of Teva group)
- 8.5.9.1. Overview
- 8.5.9.2. Financial Performance
- 8.5.9.3. Product Benchmarking
- 8.5.9.4. Strategic Initiatives
- 8.5.10. Vintage Pharmaceuticals Inc.
- 8.5.10.1. Overview
- 8.5.10.2. Financial Performance
- 8.5.10.3. Product Benchmarking
- 8.5.10.4. Strategic Initiatives
- 8.5.1. Accord Healthcare Inc.
(주말 및 공휴일 제외)
